Kotak Healthcare Fund
The scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies benefitting directly or indirectly Pharma, Healthcare, and allied sectors.
Growthvine rating: 1/5 — ranked #75 of 87 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹15.59 (as of 2026-10-23) |
|---|
| AUM | ₹768 Cr |
|---|
| Expense ratio | 1.99% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Dhananjay Tikariha |
|---|
| Exit load | 0.5% for redemption within 30 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −18.27% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 103.2% of NIFTY Pharma's upside and 101.0% of its downside.
Market cap allocation
| Large cap | 33.9% |
|---|
| Mid cap | 19.9% |
|---|
| Small cap | 46.2% |
|---|
Concentration
| Top 5 holdings | 36.5% |
|---|
| Top 10 holdings | 52.8% |
|---|
| Total holdings | 35 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 13.2%
- Divis Laboratories Ltd. — 9.4%
- Molbio Diagnostics Limited — 5.1%
- Torrent Pharmaceuticals Ltd. — 4.7%
- ACUTAAS CHEMICALS LIMITED — 4.2%
- Max Healthcare Institute Limited — 3.6%
- Cipla Ltd. — 3.3%
- PARK MEDI WORLD LIMITED — 3.2%
- Gland Pharma Limited — 3.2%
- YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED — 3.1%
Top sectors
- Pharma & Biotech — 69.0%
- Healthcare — 26.1%
- Chemicals — 3.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 17.7% | Q1 (Top) | #1 of 76 |
| 2025 | −7.3% | Q4 (Bottom) | #66 of 69 |
| 2024 | 39.5% | Q1 (Top) | #10 of 58 |